Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Free Report) – Research analysts at HC Wainwright cut their Q1 2025 EPS estimates for shares of Karyopharm Therapeutics in a note issued to investors on Wednesday, February 26th. HC Wainwright analyst E. White now anticipates that the company will post earnings per share of ($4.37) for the quarter, down from their prior forecast of ($4.35). HC Wainwright currently has a “Buy” rating and a $56.00 price objective on the stock. The consensus estimate for Karyopharm Therapeutics’ current full-year earnings is ($0.71) per share. HC Wainwright also issued estimates for Karyopharm Therapeutics’ Q2 2025 earnings at ($4.19) EPS, Q3 2025 earnings at ($3.39) EPS, Q4 2025 earnings at ($3.81) EPS, FY2025 earnings at ($15.63) EPS, FY2026 earnings at ($11.15) EPS and FY2027 earnings at ($9.05) EPS.
Karyopharm Therapeutics (NASDAQ:KPTI – Get Free Report) last released its quarterly earnings data on Wednesday, February 19th. The company reported ($3.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.90) by $0.30. The firm had revenue of $30.54 million for the quarter, compared to analyst estimates of $30.29 million.
Get Our Latest Research Report on Karyopharm Therapeutics
Karyopharm Therapeutics Price Performance
Shares of Karyopharm Therapeutics stock opened at $6.37 on Monday. The firm has a market cap of $53.64 million, a price-to-earnings ratio of -6.25 and a beta of 0.06. The stock has a 50-day simple moving average of $9.77 and a 200-day simple moving average of $11.20. Karyopharm Therapeutics has a 52-week low of $5.95 and a 52-week high of $25.50.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the company. Velan Capital Investment Management LP bought a new stake in Karyopharm Therapeutics during the fourth quarter valued at about $27,000. Focus Partners Wealth bought a new stake in Karyopharm Therapeutics during the 4th quarter valued at approximately $31,000. TD Waterhouse Canada Inc. acquired a new stake in Karyopharm Therapeutics in the 4th quarter valued at approximately $32,000. Two Sigma Advisers LP increased its position in Karyopharm Therapeutics by 145.5% in the 4th quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock worth $52,000 after buying an additional 45,400 shares during the period. Finally, Opti Capital Management LP acquired a new position in shares of Karyopharm Therapeutics during the fourth quarter worth approximately $85,000. Institutional investors own 66.44% of the company’s stock.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).
Featured Stories
- Five stocks we like better than Karyopharm Therapeutics
- The How And Why of Investing in Oil Stocks
- GitLab: Get In While It’s Down—Big Rebound Ahead
- P/E Ratio Calculation: How to Assess Stocks
- Tesla Stock: Finding a Bottom May Take Time
- What is the NASDAQ Stock Exchange?
- Duolingo: This Beaten-Down Stock Is About to Rally 38%
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.